Literature DB >> 16009904

Congenital endplate acetylcholinesterase deficiency responsive to ephedrine.

M Bestue-Cardiel1, A Sáenz de Cabezón-Alvarez, J L Capablo-Liesa, J López-Pisón, J L Peña-Segura, J Martin-Martinez, A G Engel.   

Abstract

The authors describe two patients with congenital myasthenic syndrome (CMS) with end plate acetylcholinesterase (AChE) deficiency caused by mutations in the collagenic tail (ColQ) of AChE: a homozygous C-terminal Y230S mutation in Patient 1 and Y430S and a C-terminal splice-site mutation in Patient 2. In Patient 1, a Prostigmin (neostigmine bromide) test failed to distinguish between AChE deficiency and a slow-channel CMS. Both patients responded dramatically to ephedrine therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009904     DOI: 10.1212/01.wnl.0000167132.35865.31

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  25 in total

1.  Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7.

Authors:  D Lashley; J Palace; S Jayawant; S Robb; D Beeson
Journal:  Neurology       Date:  2010-05-11       Impact factor: 9.910

2.  Beneficial effects of albuterol in congenital endplate acetylcholinesterase deficiency and Dok-7 myasthenia.

Authors:  Teerin Liewluck; Duygu Selcen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-09-23       Impact factor: 3.217

3.  Salbutamol modifies the neuromuscular junction in a mouse model of ColQ myasthenic syndrome.

Authors:  Grace M McMacken; Sally Spendiff; Roger G Whittaker; Emily O'Connor; Rachel M Howarth; Veronika Boczonadi; Rita Horvath; Clarke R Slater; Hanns Lochmüller
Journal:  Hum Mol Genet       Date:  2019-07-15       Impact factor: 6.150

4.  The potential use of ephedrine in Lambert-Eaton myasthenic syndrome : clinical and electrophysiological evaluation.

Authors:  Carlo Cereda; Thierry Kuntzer
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

5.  Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.

Authors:  Menachem Sadeh; Xin-Ming Shen; Andrew G Engel
Journal:  Muscle Nerve       Date:  2011-06-30       Impact factor: 3.217

6.  Protein-anchoring strategy for delivering acetylcholinesterase to the neuromuscular junction.

Authors:  Mikako Ito; Yumi Suzuki; Takashi Okada; Takayasu Fukudome; Toshiro Yoshimura; Akio Masuda; Shin'ichi Takeda; Eric Krejci; Kinji Ohno
Journal:  Mol Ther       Date:  2012-02-28       Impact factor: 11.454

Review 7.  Current status of the congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neuromuscul Disord       Date:  2011-11-21       Impact factor: 4.296

Review 8.  Congenital Myasthenic Syndromes: a Clinical and Treatment Approach.

Authors:  Constantine Farmakidis; Mamatha Pasnoor; Richard J Barohn; Mazen M Dimachkie
Journal:  Curr Treat Options Neurol       Date:  2018-07-21       Impact factor: 3.598

Review 9.  Further observations in congenital myasthenic syndromes.

Authors:  Andrew G Engel; Xin-Ming Shen; Duygu Selcen; Steven M Sine
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

Review 10.  The therapy of congenital myasthenic syndromes.

Authors:  Andrew G Engel
Journal:  Neurotherapeutics       Date:  2007-04       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.